

Table S1. SNPs information and genotyping results for RA patients and control group.

| SNP ID | Allele | SNP Type/ Amino Acid Change | MAF | | |
|------------------|----------|-----------------------------------|------|---------|----------------|
| | | | RA | Control | HapMap- CEU |
| rs1870377 | +1416A/T | exon 11 H472Q | 0.32 | 0.27 | 0.21 |
| rs2305948 | +889 G/A | exon 7 V297I | 0.18 | 0.14 | 0.15 |
| rs2071559 | -604 C/T | promoter region | 0.48 | 0.60 | 0.50 |

MAF - minor allele frequency; CEU - Utah residents of northern and western European ancestry; UTR – untranslated region

Table S2. Association between genotypes of KDR+1416A/T and clinical characteristics among RA patients.

| Parameter | AA | | AT+TT | | p* |
|-----------------------------------|-----|--------------------|-------|--------------------|-------------|
| | N | median (IQR) | N | median (IQR) | |
| Age [years] | 447 | 50 (32 - 60) | 448 | 51.5 (34.5 – 60) | 0.612 |
| Disease duration [years] | 239 | 10 (5 - 16) | 267 | 9 (4 – 15) | 0.116 |
| Larsen | 255 | 3 (3 -4) | 282 | 3 (2 - 3) | 0.334 |
| Number of tender joints | 152 | 7 (2 – 11) | 163 | 8 (4 -13) | 0.130 |
| Number of swollen joints | 152 | 3 (1 – 7) | 165 | 3 (1 – 8) | 0.217 |
| ESR [mm/h] | 251 | 30 (17 – 51) | 284 | 30 (16 – 50) | 0.586 |
| CRP [mg/L] | 153 | 14 (6 – 32) | 169 | 11.7 (5.3 – 32) | 0.329 |
| Hemoglobin [g/dL] | 154 | 12.6 (11.7 – 13.4) | 168 | 12.8 (11.7 – 13.7) | 0.604 |
| VAS [mm] | 147 | 51 (30 – 71) | 161 | 53 (34 – 70) | 0.575 |
| DAS 28-CRP | 147 | 5 (3.8 – 5.7) | 164 | 5 (3.8 – 5.9) | 0.454 |
| HAQ | 129 | 1.62 (1 – 2) | 136 | 1.5 (1 – 2) | 0.398 |
| PLT [$\times 10^3/\text{mm}^3$] | 153 | 305 (290 – 350) | 168 | 308 (251 – 369) | 0.911 |
| Creatinine | 153 | 0.7 (06 – 0.8) | 166 | 0.7 (06 – 0.8) | 0.481 |
| | | | | | p** |
| | N | n (%) | N | n (%) | |
| Women | 450 | 349 (82%) | 448 | 369 (78%) | 0.07 |
| RF presence | 251 | 158 (63%) | 283 | 203 (72%) | 0.03 |
| anti-CCP presence | 154 | 116 (75%) | 171 | 141 (82%) | 0.114 |

Table S3. Association between genotypes of KDR -604 C/T and clinical characteristics among RA patients.

| Parameter | TT | | TC+CC | | p* |
|-----------------------------------|-----|--------------------|-------|--------------------|--------------|
| | N | median (IQR) | N | median (IQR) | |
| Age [years] | 175 | 55 (48 – 63) | 777 | 48 (30 – 59) | 0.679 |
| Disease duration [years] | 135 | 10 (5 - 16) | 388 | 10 (4.5 – 15.5) | 0.748 |
| Larsen | 145 | 3 (3 – 4) | 420 | 3 (2 – 4) | 0.241 |
| Number of tender joints | 81 | 8 (3 – 13) | 256 | 7 (3 – 11) | 0.466 |
| Number of swollen joints | 83 | 4 (1 - 7) | 256 | 3 (1 – 7) | 0.483 |
| ESR [mm/h] | 144 | 31 (18 - 50) | 419 | 30 (16 – 50) | 0.728 |
| CRP [mg/L] | 83 | 18 (7 - 40) | 260 | 12 (6 – 30) | 0.066 |
| Hemoglobin [g/dL] | 84 | 12.3 (11.4 – 13.2) | 259 | 12.8 (11.8 – 13.6) | 0.122 |
| VAS [mm] | 79 | 55 (40 – 72) | 251 | 52 (32 – 71) | 0.525 |
| DAS 28-CRP | 80 | 5.6 (4.1 – 6.2) | 253 | 5 (3.9 – 6.7) | 0.138 |
| HAQ | 71 | 1.5 (1 – 2) | 215 | 1.5 (1 – 2) | 0.670 |
| PLT [$\times 10^3/\text{mm}^3$] | 84 | 310 (260 – 375) | 258 | 305 (245 – 381) | 0.605 |
| Creatinine | 82 | 0.7 (0.6 – 0.8) | 258 | 0.7 (0.6 – 0.8) | 0.977 |
| | | | | | p** |
| | N | n (%) | N | n (%) | |
| Women | 176 | 149 (85%) | 779 | 607 (88%) | 0.046 |
| RF presence | 144 | 99 (69%) | 415 | 286 (69%) | 0.970 |
| anti-CCP presence | 84 | 65 (77%) | 262 | 213 (81%) | 0.431 |